I-Mab

163 articles with I-Mab

• I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

  3/20/2023

  I-Mab today announced that the Company will report financial results for the full year ended December 31, 2022 before the market opens on Friday March 31, 2023, and host a conference call to discuss the results and provide a corporate update at 8:15 a.m. EST.

• I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

  10/5/2022

   I-Mab today announced that the Company will present new preclinical data of its core assets lemzoparlimab and uliledlimab, respectively, at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, as well as virtually November 8-12, 2022. 

• I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

  9/13/2022

  I-Mab today announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting with the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), and has obtained approval from the CDE to initiate a Phase 3 registrational trial evaluating lemzoparlimab,

• I-Mab Announces Oral Presentation of Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

  9/6/2022

  I-Mab (the "Company") (Nasdaq: IMAB), today announced that the results from its Phase 2 clinical study of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with higher risk myelodysplastic syndrome (HR-MDS) will be featured in a proffered paper presentation at the upcoming European Society for Medical Oncology (ESMO) Congress 2022.

• I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022

  8/30/2022

  I-Mab will host conference calls and webcasts on August 30, 2022. A Mandarin session will be held at 7:00 a.m. ET and an English session will be held at 8:15 a.m. ET.

• I-Mab Announces Share Purchase Plans by the Company and the Senior Management

  8/23/2022

  I-Mab today announced that it plans to implement share repurchases pursuant to the share repurchase program previously authorized by its Board of Directors.

• I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022

  8/19/2022

  I-Mab today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2022, before the market opens on Tuesday, August 30, 2022.

• 

  Despite $2B AML Deal, AbbVie Stops Early Cancer Combo Trial With I-Mab

  8/17/2022

  I-Mab quietly announced that its partner AbbVie is ending a Phase IB trial on lemzoparlimab for two types of cancers, despite a $2 billion deal inked in 2020.

• I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China

  7/22/2022

  I-Mab today announced that the first patient in China has been treated with TJ-CD4B (also known as ABL111).

• I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

  7/18/2022

  I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data from a Phase 2 study of lemzoparlimab.

• I-Mab to Host 2022 R&D Day

  7/6/2022

  I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will host its 2022 Research and Development (R&) Day on July 20, 2022.

• I-Mab Receives Top Rankings in Five Categories by Institutional Investor

  6/23/2022

  I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies in five different categories by leading global financial publication.

• I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

  6/15/2022

  I-Mab today announced two assets the Company has licensed from partner MorphoSys AG (FSE: MOR; NASDAQ: MOR), felzartamab (also known as TJ202/MOR202) and TJ210 (also known as MOR210), are advancing globally through new license agreements.

• Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

  6/14/2022

  Genexine announced that its partner, I-Mab, recently completed patient enrollment in a phase 3 clinical trial of its proprietary long-acting growth hormone, eftansomatropin alfa, also known as GX-H9/TJ101, in China, taking it one step closer to commercialization in a key market.

• I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency

  5/31/2022

  I-Mab (the "Company") (Nasdaq: IMAB), today announced the completion of patient enrollment in a Phase 3 clinical trial (TALLER) of highly differentiated long-acting recombinant human growth hormone eftansomatropin alfa (also known as TJ101), which is being investigated as a weekly treatment for pediatric growth hormone deficiency (PGHD) in China.

• I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

  5/26/2022

  I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced preliminary data of its ongoing Phase 2 clinical trial (NCT04322006) with uliledlimab (also known as TJD5, or TJ004309), a differentiated CD73 antibody, and its global clinical development plan.

• I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

  5/19/2022

  I-Mab (the "Company") (Nasdaq" IMAB), today announced that it will hold a call with investors at 8 a.m. EST on May 27th to present preliminary data from an ongoing phase 2 clinical trial of its differentiated CD73 antibody uliledlimab (also known as TJD5, or TJ004309) and the global clinical development plan.

• 

  SEC Tightens Screws on Chinese Companies with Delisting Efforts

  5/6/2022

  The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.

• I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act

  5/5/2022

  I-Mab  today provided updates on its status under the Holding Foreign Companies Accountable Act (the "HFCAA").

• I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

  4/28/2022

  I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the appointments of Mr. Richard Yeh as Chief Operating Officer and Dr. John Hayslip as Chief Medical Officer.